Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.

@article{Zhang2009PopulationPO,
  title={Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.},
  author={Jing Zhang and Jun-Fang Xu and Yan-Bin Liu and Zu-ke Xiao and Jian-an Huang and Bin Si and Sheng-hua Sun and Qian-ming Xia and Xiao-jie Wu and Guo-ying Cao and Yao-guo Shi and Ying-yuan Zhang},
  journal={Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy},
  year={2009},
  volume={15 5},
  pages={
          293-300
        }
}
This study aimed to explore the pharmacokinetic features of levofloxacin (LVFX) in Chinese patients with infections and to confirm oral LVFX 500 mg once daily as an optimal treatment regimen based on pharmacokinetic-pharmacodynamic (PK-PD) analysis. A total of 1052 plasma samples from 164 Chinese adult patients with community acquired lower respiratory tract infections (CALRTIs) and 18 healthy volunteers were used for population PK analysis. LVFX 500-mg tablets were given once daily. A… CONTINUE READING
BETA